PMID- 35983400
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220820
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 7
DP  - 2022 Jul
TI  - Clinical and Epidemiological Profile of Elderly Hodgkin's Lymphoma in India.
PG  - e26906
LID - 10.7759/cureus.26906 [doi]
LID - e26906
AB  - Background Hodgkin's lymphoma (HL) is a curable malignancy that commonly involves 
      the younger population. However, HL can rarely occur in the elderly population 
      (>/=60 years) and probably has different biology as compared to the younger 
      counterparts. There was a paucity of data on the clinical and epidemiological 
      profile of the elderly subset with HL in Indian patients who are misdiagnosed and 
      empirically treated as tuberculosis. We have done an analysis of this subset of 
      elderly patients who were registered at our institute. Methods A retrospective 
      chart analysis of HL patients who presented to our center from 2008 to 2016 was 
      conducted. Twenty-eight patients with HL of age >/=60 years were included in this 
      study. Results Elderly HL comprised 18.67% of the total HL patients registered 
      during this period. The majority were male patients, and the mean age of 
      presentation was 65.9+/-5.6 years. A Charlson Comorbidity Index (CCI) of >/=2 was 
      seen in 30.77% of the patients. Among these, 84.62% of the patients presented 
      with advanced-stage disease, and 57.69% of the patients presented with B 
      symptoms, which was significantly associated with a high-risk international 
      prognostic score (IPS). Histology-wise, mixed cellularity classical Hodgkin's 
      lymphoma (MCCHL) and nodular sclerosis classical Hodgkin's lymphoma (NSCHL) were 
      equally represented (30.76%). Of the patients, 50% had extranodal disease, with 
      the liver being the most frequent site involved. One patient each had bone marrow 
      involvement and bulky disease. CD30, CD15, and CD20 positivity was seen in 
      84.61%, 50%, and 26.92% of cases, respectively. Conclusion Among elderly HL 
      patients, males were more commonly represented than females, and patients more 
      often presented with advanced disease and B symptoms and less often with bulky 
      disease and mediastinal mass. Mixed cellularity classical HL is more common in 
      the elderly subset, and significant comorbidities are present in a higher number 
      of elderly HL patients.
CI  - Copyright (c) 2022, Sharma et al.
FAU - Sharma, Manish
AU  - Sharma M
AD  - Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 
      IND.
FAU - Goyal, Pankaj
AU  - Goyal P
AD  - Medical Oncology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, 
      New Delhi, IND.
FAU - Ranjan, Rajesh
AU  - Ranjan R
AD  - Community Medicine, Noida International Institute of Medical Sciences, Gautam 
      Budh Nagar, IND.
FAU - Maheshwari, Udip
AU  - Maheshwari U
AD  - Medical Oncology, Mumbai Oncocare Centre, Mumbai, IND.
FAU - Bhurani, Dinesh
AU  - Bhurani D
AD  - Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New 
      Delhi, IND.
FAU - Aggarwal, Chaturbhuj
AU  - Aggarwal C
AD  - Medical Oncology, Bahrain Specialist Hospital, Manama, BHR.
FAU - Koyyala, Venkata Pradeep Babu
AU  - Koyyala VPB
AD  - Medical Oncology, Assam Cancer Care Foundation, Tezpur, IND.
AD  - Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 
      IND.
FAU - Jain, Parveen
AU  - Jain P
AD  - Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, 
      IND.
FAU - Agrawal, Narendra
AU  - Agrawal N
AD  - Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IND.
FAU - Ahmed, Rayaz
AU  - Ahmed R
AD  - Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IND.
LA  - eng
PT  - Journal Article
DEP - 20220715
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC9376209
OTO - NOTNLM
OT  - cd positivity
OT  - elderly
OT  - hodgkin's lymphoma
OT  - immunohistochemistry
OT  - malignancy
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/08/20 06:00
MHDA- 2022/08/20 06:01
PMCR- 2022/07/15
CRDT- 2022/08/19 02:19
PHST- 2022/07/08 00:00 [accepted]
PHST- 2022/08/19 02:19 [entrez]
PHST- 2022/08/20 06:00 [pubmed]
PHST- 2022/08/20 06:01 [medline]
PHST- 2022/07/15 00:00 [pmc-release]
AID - 10.7759/cureus.26906 [doi]
PST - epublish
SO  - Cureus. 2022 Jul 15;14(7):e26906. doi: 10.7759/cureus.26906. eCollection 2022 
      Jul.